Original Scientific Articles
Download PDF (823.07 KB)
Journal of Structural Heart Disease, February 2017, Volume 3, Issue 1:1-7
DOI: 10.12945/j.jshd.2016.002.16
The Occlutech Duct Occluder for Patent Ductus Arteriosus
Najib Hanna, MD1, Ramy Charbel, MD2*, Ghassan Chehab, MD1, Bernard Gerbaka, MD2, Zakhia Saliba, MD1
1 Hotel-Dieu de France University Medical Center, Department of Pediatric Cardiology, Saint Joseph University, Naccache Boulevard, Achrafieh, Lebanon
2 Hotel-Dieu de France University Medical Center, Department of Pediatrics, Saint Joseph University, Naccache Boulevard, Achrafieh, Lebanon
Abstract
Objective: To describe our experience in percutaneous Patent Ductus Arteriosus (PDA) closure using the Occlutech Duct Occluder (ODO).
Methods: We retrospectively reviewed patients who underwent an attempt for PDA closure with ODO between August 2013 and October 2015. Only patients with isolated PDA and weighing ≥ 6 kg were eligible for the ODO use.
Results: Eighteen ODO devices were successfully implanted in 18 patients. Age and weight ranged from 6 to 180 months (median 23.5) and 6 to 54 kg (median 11), respectively. PDA was of type A (16 patients), type E (1) and type D (1). PDA diameter ranged from 2 to 5 mm (median 3). Median procedure time was 55 minutes (range 35 to105). Median fluoroscopy time was 9.2 minutes (range 3 to 29.57). The device diameter (pulmonary end) was 5 to 8 mm (median 7). The standard shank length was used in 13 cases and the long variant in the remaining 5. Median follow-up period was 12 months. All devices were successfully implanted. Total occlusion was achieved the following day in all but 2 in whom it was confirmed 1 month later. No major complication occurred. Mild pulmonary obstruction was noted in one patient and aortic disc bulging occurred in 2 others, without hemodynamic consequences.
Conclusion: In this group of patients, the ODO has shown excellent results in terms of safety and efficiency. The long device variant may be advantageous in some large and long PDAs. Larger series are needed to compare it with the preexisting devices.
Cite this article as: Hanna N, Charbel R, Chehab G, Gerbaka B, Saliba Z. The Occlutech Duct Occluder for Patent Ductus Arteriosus. Structural Heart Disease 2017;3(1):1-7. DOI: 10.12945/j.jshd.2016.002.16
All comments will be screened and reviewed before posting. Statements, opinions, and results of studies published in Journal of Structural Heart Disease are those of the authors and do not reflect the policy or position of The Journal and Science International and the Editorial Board and provides no warranty as to their accuracy or reliability. Material is copyrighted and owned by Science International and cannot be used without expressed permission.
Original Scientific Articles
Journal of Structural Heart Disease, February 2017, Volume 3, Issue 1:1-7
DOI: 10.12945/j.jshd.2016.002.16
The Occlutech Duct Occluder for Patent Ductus Arteriosus
Najib Hanna, MD1, Ramy Charbel, MD2*, Ghassan Chehab, MD1, Bernard Gerbaka, MD2, Zakhia Saliba, MD1
1 Hotel-Dieu de France University Medical Center, Department of Pediatric Cardiology, Saint Joseph University, Naccache Boulevard, Achrafieh, Lebanon
2 Hotel-Dieu de France University Medical Center, Department of Pediatrics, Saint Joseph University, Naccache Boulevard, Achrafieh, Lebanon
Abstract
Objective: To describe our experience in percutaneous Patent Ductus Arteriosus (PDA) closure using the Occlutech Duct Occluder (ODO).
Methods: We retrospectively reviewed patients who underwent an attempt for PDA closure with ODO between August 2013 and October 2015. Only patients with isolated PDA and weighing ≥ 6 kg were eligible for the ODO use.
Results: Eighteen ODO devices were successfully implanted in 18 patients. Age and weight ranged from 6 to 180 months (median 23.5) and 6 to 54 kg (median 11), respectively. PDA was of type A (16 patients), type E (1) and type D (1). PDA diameter ranged from 2 to 5 mm (median 3). Median procedure time was 55 minutes (range 35 to105). Median fluoroscopy time was 9.2 minutes (range 3 to 29.57). The device diameter (pulmonary end) was 5 to 8 mm (median 7). The standard shank length was used in 13 cases and the long variant in the remaining 5. Median follow-up period was 12 months. All devices were successfully implanted. Total occlusion was achieved the following day in all but 2 in whom it was confirmed 1 month later. No major complication occurred. Mild pulmonary obstruction was noted in one patient and aortic disc bulging occurred in 2 others, without hemodynamic consequences.
Conclusion: In this group of patients, the ODO has shown excellent results in terms of safety and efficiency. The long device variant may be advantageous in some large and long PDAs. Larger series are needed to compare it with the preexisting devices.
PDF
Mobile-ready Flipbook
Cite this article as: Hanna N, Charbel R, Chehab G, Gerbaka B, Saliba Z. The Occlutech Duct Occluder for Patent Ductus Arteriosus. Structural Heart Disease 2017;3(1):1-7. DOI: 10.12945/j.jshd.2016.002.16
You must be registered and logged in to leave comments.
There have been no comments posted yet
Ask a question (publicly)
Board